• Founder(s): Dr. Michael Thompson, Dr. Norbert Höfgen, Prof. Yixin Zhang, Dr. Francesco Reddavide, Dr. Jana Herrmann & Dr. Luca Mannocci
  • Established: April 2017
  • CEO(s): Dr. Michael Thompson
  • Employees: 4
  • Financial Data: Privately funded
  • Website:


DyNAbind’s mission is to empower researchers with the tools they need to discover and optimize drug candidates for a new generation of challenging targets.

For this purpose, DyNAbind uses a novel DNA-encoded library technology platform to simultaneously analyze millions of different chemicals against a drug target of interest. The company’s patent protected innovations provide a better route to higher-quality, more relevant medicinal chemistry starting points at ten times the speed and one-tenth the cost of traditional methodologies.

Located in Dresden, the company can keep up its cooperation with the TU Dresden’s bioengineering center. Also, the modest cost of living provides favorable conditions for founding and growing a startup.

The team of DyNAbind represents four countries and speaks five languages, which reflects the diversity of the global pharmaceutical market.